Vaccine Confidence Study Among Historically Marginalized Racial and Ethnic Groups
NCT06639386 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 80
Last updated 2026-04-07
Summary
Achieving optimal vaccination rates is vital for protecting the health and well-being of all individuals. This specific study focuses on the MMR and RSV vaccines in pregnancy and early childhood, which have been shown to reduce RSV and MMR-related illnesses, hospitalizations, and deaths. Efforts to improve vaccination rates have not been equally effective across the entire population; this has resulted in poorer outcomes from interventions for certain populations who are vaccine-hesitant.
This study seeks to understand how to best increase vaccine confidence in marginalized populations. To do this, the investigators will interview parents of children who receive care at Boston Medical Center (BMC), Community Health Workers and other Clinical providers at BMC, leading experts in the fields of vaccine confidence and implementation science, and key public health stakeholders/officials.
Conditions
- Vaccine Hesitancy
- Vaccine Refusal
Sponsors & Collaborators
- collaborator INDUSTRY
-
Boston Medical Center
lead OTHER
Principal Investigators
-
Michelle Stransky, PhD · Boston Medical Center, Pediatrics
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2025-01-31
- Primary Completion
- 2026-05-31
- Completion
- 2026-05-31
Countries
- United States
Study Locations
More Related Trials
-
Culturally Targeted Health Communication and Receptivity to the Human Papillomavirus Vaccine Among Parents in Flint, MI
NCT07301905 ·Status: RECRUITING ·Phase: NA
-
Improving HPV Vaccination Rates Among Rural and Native American Adolescents
NCT03801603 ·Status: COMPLETED ·Phase: NA
-
A Study of an Investigational V212/Heat-Treated Varicella-Zoster Virus (VZV) Vaccine in Immunocompromised Adults (V212-002)
NCT00535236 ·Status: COMPLETED ·Phase: PHASE1
-
Immunogenicity and Safety of GSK Biologicals' Combined Measles-mumps-rubella Vaccine in Volunteers, Seven Years of Age and Older
NCT02058563 ·Status: COMPLETED ·Phase: PHASE3
-
Comparison of Immunization Quality Improvement Dissemination Study
NCT02432430 ·Status: COMPLETED ·Phase: NA
-
A Study to Learn About a Modified RNA Vaccine Against Shingles in Healthy Adults
NCT05703607 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
Tailoring of Vaccine-Focused Messages: Disease Salience
NCT03002324 ·Status: COMPLETED ·Phase: NA
-
Epstein-Barr Virus (EBV) gH/gL/gp42-Ferritin Nanoparticle Vaccine With or Without gp350-Ferritin in Healthy Adults With or Without EBV Infection
NCT06908096 ·Status: RECRUITING ·Phase: PHASE1
-
A Study to Evaluate Safety, Tolerability, and Immunogenicity of an Investigational Zoster Vaccine In Subjects With a History of Varicella (Chickenpox)(V211-010)(COMPLETED)
NCT00130793 ·Status: COMPLETED ·Phase: PHASE3
-
Immunity in Persons Fully Vaccinated Against Measles, Mumps and Rubella and Responses to Booster Vaccination
NCT05894395 ·Status: RECRUITING ·Phase: PHASE3
-
Safety, Reactogenicity and Immunogenicity of a Novel MVA-SARS-2-ST Vaccine Candidate
NCT05226390 ·Status: TERMINATED ·Phase: PHASE1
-
Parents' HPV Stories
NCT06704308 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
Broad Spectrum HPV Vaccine Tolerability, Immunogenicity, and Efficacy Study (V502-003)
NCT00365443 ·Status: WITHDRAWN ·Phase: PHASE2
-
A Study to Evaluate Safety, Tolerability, & Immunogenicity of Multiple Formulations of BNT162b2 Against COVID-19 in Healthy Adults
NCT04816669 ·Status: COMPLETED ·Phase: PHASE3
-
Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Combined Measles-mumps-rubella (MMR) Vaccine in Subjects Four to Six Years of Age
NCT01621802 ·Status: COMPLETED ·Phase: PHASE3
-
Prospective Trial of Vaccine Responses in Childhood Cancer Survivors
NCT00505063 ·Status: COMPLETED ·Phase: PHASE2
-
PREVENT Pilot HPV - Related Cancers Trial
NCT06738355 ·Status: COMPLETED ·Phase: NA
-
Safety, Tolerability, and Immunogenicity of Measles, Mumps, Rubella, and Varicella (MMRV) Vaccine Made With an Alternative Manufacturing Process (AMP)(V221-027)
NCT01536405 ·Status: COMPLETED ·Phase: PHASE3
-
Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Meningococcal Vaccine With or Without Co-administration of Cervarix and Boostrix in Female Adolescents and Young Adults
NCT01755689 ·Status: COMPLETED ·Phase: PHASE3
-
Study to Evaluate Frozen Versus Refrigerated MMRV (Combined Measles, Mumps, Rubella, and Varicella) Investigational Vaccine (V221-016)
NCT00092430 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1468 in Healthy Adults ≥50 Years of Age
NCT05701800 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
Developing and Evaluating a Novel Approach to Improve HPV Vaccination Coverage Among High-risk, Under-immunized Adults Via the Emergency Department
NCT06229353 ·Status: TERMINATED
-
A Study to Evaluate Immunity to Varicella Zoster Virus After Immunization With V212 Vaccine or Zostavax (V212-003)
NCT00886613 ·Status: COMPLETED ·Phase: PHASE1
-
Investigating HPV Vaccination Uptake in Adults Aged 18-35 Seeking Care at a Health Clinic in Rural Mississippi
NCT05658198 ·Status: ENROLLING_BY_INVITATION
-
Safety and Immunogenicity of Venezuelan Equine Encephalomyelitis Vaccine in Healthy Adults
NCT03051386 ·Status: UNKNOWN ·Phase: PHASE2